• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Beta-adrenergic receptor blockers. Adverse effects and drug interactions.

作者信息

Frishman W H

机构信息

Department of Medicine, Albert Einstein College of Medicine, Bronx, New York.

出版信息

Hypertension. 1988 Mar;11(3 Pt 2):II21-9. doi: 10.1161/01.hyp.11.3_pt_2.ii21.

DOI:10.1161/01.hyp.11.3_pt_2.ii21
PMID:2895072
Abstract

Adverse effects of beta-adrenergic receptor blocking drugs can be divided into two categories: 1) those that result from known pharmacological consequences of beta-adrenergic receptor blockade; and 2) other reactions that do not appear to result from beta-adrenergic receptor blockade. Adverse effects of the first type include bronchospasm, heart failure, prolonged hypoglycemia, bradycardia, heart block, intermittent claudication, and Raynaud's phenomenon. Neurological reactions include depression, fatigue, and nightmares. It is not yet proven whether the beta 1-selective adrenergic blockers or those with partial agonist activity reduce the overall frequency of adverse reactions seen with propranolol. Patient age does not appear, in itself, to be associated with more beta-blocker side effects. Side effects of the second category are rare. They include an unusual oculomucocutaneous reaction and the possibility of oncogenesis. There are also many drugs that interact with beta-blockers, which may increase toxicity. Finally, there are specific patient characteristics where one beta-blocker may be more effective and safer than another.

摘要

相似文献

1
Beta-adrenergic receptor blockers. Adverse effects and drug interactions.
Hypertension. 1988 Mar;11(3 Pt 2):II21-9. doi: 10.1161/01.hyp.11.3_pt_2.ii21.
2
Adverse reactions and interactions with beta-adrenoceptor blocking drugs.β-肾上腺素能受体阻断药的不良反应及相互作用。
Med Toxicol. 1986 Sep-Oct;1(5):343-61. doi: 10.1007/BF03259848.
3
Clinical pharmacology of adrenergic-adrenoreceptor-blocking drugs.
Am Heart J. 1982 Aug;104(2 Pt 2):407-12. doi: 10.1016/0002-8703(82)90130-2.
4
Alpha- and beta-receptor blocking drugs in the treatment of hypertension.α和β受体阻断药治疗高血压
Curr Probl Cardiol. 1979 Jan;3(10):1-53.
5
Systemic adverse effects of beta-adrenergic blockers: an evidence-based assessment.β-肾上腺素能阻滞剂的全身性不良反应:基于证据的评估。
Am J Ophthalmol. 2002 Nov;134(5):749-60. doi: 10.1016/s0002-9394(02)01699-9.
6
Beta blockers in hypertension: a review.β受体阻滞剂治疗高血压:综述
Am J Hosp Pharm. 1976 Dec;33(12):1284-90.
7
CNS-related (side-)effects of beta-blockers with special reference to mechanisms of action.β受体阻滞剂与中枢神经系统相关的(副作用),特别提及作用机制。
Eur J Clin Pharmacol. 1985;28 Suppl:55-63. doi: 10.1007/BF00543711.
8
Beta-Adrenergic Receptor Blockers in Hypertension: Alive and Well.β-肾上腺素能受体阻滞剂在高血压中的应用:仍然有效。
Prog Cardiovasc Dis. 2016 Nov-Dec;59(3):247-252. doi: 10.1016/j.pcad.2016.10.005. Epub 2016 Oct 28.
9
Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction.β受体阻滞剂治疗与抑郁、疲劳及性功能障碍症状
JAMA. 2002 Jul 17;288(3):351-7. doi: 10.1001/jama.288.3.351.
10
Do we need a new classification of beta-blockers?我们是否需要一种新的β受体阻滞剂分类?
J Hum Hypertens. 1990 Jun;4 Suppl 2:27-9.

引用本文的文献

1
Novel approaches to clinical trial design in cancer neuroscience.癌症神经科学临床试验设计的新方法。
Neuron. 2025 Sep 3;113(17):2791-2813. doi: 10.1016/j.neuron.2025.08.015.
2
Exposure to metoprolol and propranolol mixtures on biochemical, immunohistochemical, and molecular alterations in the American oyster, .美牡蛎暴露于美托洛尔和普萘洛尔混合物下的生化、免疫组织化学及分子变化
Toxicol Rep. 2025 Mar 4;14:101979. doi: 10.1016/j.toxrep.2025.101979. eCollection 2025 Jun.
3
Elucidation of the Molecular Mechanism of Compound Danshen Dripping Pills against Angina Pectoris based on Network Pharmacology and Molecular Docking.
基于网络药理学和分子对接技术解析复方丹参滴丸抗心绞痛的分子机制。
Curr Pharm Des. 2024;30(16):1247-1264. doi: 10.2174/0113816128287109240321074628.
4
Hemodynamic and Rhythmologic Effects of Push-Dose Landiolol in Critical Care-A Retrospective Cross-Sectional Study.推注剂量兰地洛尔在重症监护中的血流动力学和节律学效应——一项回顾性横断面研究
Pharmaceuticals (Basel). 2023 Jan 17;16(2):134. doi: 10.3390/ph16020134.
5
Assessing the Risk of Hypoglycemia Secondary to Propranolol Therapy for the Treatment of Supraventricular Tachycardia in Infants.评估普萘洛尔治疗婴儿室上性心动过速继发低血糖的风险。
Pediatr Cardiol. 2023 Apr;44(4):836-844. doi: 10.1007/s00246-023-03142-9. Epub 2023 Mar 18.
6
Design and rationale of randomized evaluation of decreased usage of beta-blockers after acute myocardial infarction (REDUCE-AMI).随机评估急性心肌梗死后减少β受体阻滞剂使用的设计和原理(RE- DUCE-AMI)。
Eur Heart J Cardiovasc Pharmacother. 2023 Feb 2;9(2):192-197. doi: 10.1093/ehjcvp/pvac070.
7
The Role of Beta-Adrenergic Receptors in Depression and Resilience.β-肾上腺素能受体在抑郁和恢复力中的作用。
Biomedicines. 2022 Sep 23;10(10):2378. doi: 10.3390/biomedicines10102378.
8
Targeting tumor innervation: premises, promises, and challenges.靶向肿瘤神经支配:前提、前景与挑战。
Cell Death Discov. 2022 Mar 25;8(1):131. doi: 10.1038/s41420-022-00930-9.
9
Effectiveness and safety assessment of beta-blockers, calcium channel blockers, and angiotensin receptor blockers in hypertensive patients: a prospective study.β受体阻滞剂、钙通道阻滞剂和血管紧张素受体阻滞剂在高血压患者中的有效性和安全性评估:一项前瞻性研究。
Am J Cardiovasc Dis. 2021 Oct 25;11(5):601-610. eCollection 2021.
10
Towards Drug Repurposing in Cancer Cachexia: Potential Targets and Candidates.癌症恶病质中药物再利用的研究进展:潜在靶点与候选药物
Pharmaceuticals (Basel). 2021 Oct 26;14(11):1084. doi: 10.3390/ph14111084.